BR112023022474A2 - Composições de fator de crescimento para o tratamento de doença ocular - Google Patents
Composições de fator de crescimento para o tratamento de doença ocularInfo
- Publication number
- BR112023022474A2 BR112023022474A2 BR112023022474A BR112023022474A BR112023022474A2 BR 112023022474 A2 BR112023022474 A2 BR 112023022474A2 BR 112023022474 A BR112023022474 A BR 112023022474A BR 112023022474 A BR112023022474 A BR 112023022474A BR 112023022474 A2 BR112023022474 A2 BR 112023022474A2
- Authority
- BR
- Brazil
- Prior art keywords
- growth factor
- treatment
- eye disease
- compositions
- factor compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188816P | 2021-05-14 | 2021-05-14 | |
| PCT/US2022/072302 WO2022241465A1 (en) | 2021-05-14 | 2022-05-13 | Compositions of growth factor for the treatment of eye disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022474A2 true BR112023022474A2 (pt) | 2024-01-09 |
Family
ID=81756753
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022474A BR112023022474A2 (pt) | 2021-05-14 | 2022-05-13 | Composições de fator de crescimento para o tratamento de doença ocular |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230022990A1 (enExample) |
| EP (2) | EP4574211A3 (enExample) |
| JP (1) | JP2024518178A (enExample) |
| KR (1) | KR20240035394A (enExample) |
| CN (1) | CN117677394A (enExample) |
| AU (1) | AU2022272740A1 (enExample) |
| BR (1) | BR112023022474A2 (enExample) |
| CA (1) | CA3218000A1 (enExample) |
| IL (1) | IL308496A (enExample) |
| MX (1) | MX2023012782A (enExample) |
| TW (1) | TW202310868A (enExample) |
| WO (1) | WO2022241465A1 (enExample) |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| DE3169595D1 (en) | 1980-11-10 | 1985-05-02 | Gersonde Klaus | Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| ATE159858T1 (de) | 1983-09-26 | 1997-11-15 | Ehrenfeld Udo | Mittel und erzeugnis für die diagnose und therapie von tumoren sowie zur behandlung von schwächen der zelligen und humoralen immunabwehr |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US5510329A (en) * | 1988-04-26 | 1996-04-23 | Ramot University For Applied Research And Industrial Development Ltd. | Preparations for the treatment of eyes |
| NZ232813A (en) | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
| JP3927248B2 (ja) | 1995-07-11 | 2007-06-06 | 第一製薬株式会社 | Ｈｇｆ凍結乾燥製剤 |
| JP2000344680A (ja) * | 1999-05-31 | 2000-12-12 | Mitsubishi Chemicals Corp | Ｈｇｆ含有医薬組成物 |
| ATE359809T1 (de) | 1999-05-31 | 2007-05-15 | Mitsubishi Chem Corp | Gefriergetrocknete hgf-präparationen |
| AU2003272536A1 (en) * | 2002-09-18 | 2004-04-08 | Emiliano Ghinelli | Use of a human amniotic membrane composition for prophylaxis and treatment of diseases and conditions of the eye and skin |
| EP2014676B1 (en) * | 2006-04-20 | 2012-03-07 | Kringle Pharma Inc. | Hgf precursor protein mutant and activated form thereof |
| WO2008102452A1 (ja) | 2007-02-22 | 2008-08-28 | Kringle Pharma Inc. | Ｈｇｆ製剤 |
| US8895508B2 (en) * | 2009-07-24 | 2014-11-25 | Yasuhiki Tabata | Methods for corneal endothelial proliferation using bFGF sustained-release gelatin hydrogel particles |
| CA2947396C (en) * | 2014-04-28 | 2021-10-19 | Eisai R&D Management Co., Ltd. | Lyophilized formulation of hgf |
| WO2016039163A1 (ja) | 2014-09-10 | 2016-03-17 | クリングルファーマ株式会社 | 神経疾患の治療に適したｈｇｆ製剤 |
| US10449234B2 (en) | 2015-09-11 | 2019-10-22 | The Schepens Eye Research Institute, Inc. | Compositions and methods for prevention and treatment of corneal haze and scarring |
| DK3619324T3 (da) * | 2017-05-05 | 2025-09-22 | Trefoil Therapeutics Inc | Rekombinante modificerede fibroblast-vækstfaktorer og terapeutiske anvendelser heraf |
| JP2023532046A (ja) * | 2020-06-26 | 2023-07-26 | トレフォイル セラピューティクス，インク． | 組換え修飾線維芽細胞増殖因子およびそれを使用した治療 |
-
2022
- 2022-05-13 IL IL308496A patent/IL308496A/en unknown
- 2022-05-13 BR BR112023022474A patent/BR112023022474A2/pt unknown
- 2022-05-13 EP EP25163012.5A patent/EP4574211A3/en active Pending
- 2022-05-13 KR KR1020237042977A patent/KR20240035394A/ko active Pending
- 2022-05-13 MX MX2023012782A patent/MX2023012782A/es unknown
- 2022-05-13 CN CN202280047869.4A patent/CN117677394A/zh active Pending
- 2022-05-13 TW TW111118098A patent/TW202310868A/zh unknown
- 2022-05-13 US US17/743,488 patent/US20230022990A1/en active Pending
- 2022-05-13 CA CA3218000A patent/CA3218000A1/en active Pending
- 2022-05-13 EP EP22725696.3A patent/EP4337243A1/en active Pending
- 2022-05-13 JP JP2023570358A patent/JP2024518178A/ja active Pending
- 2022-05-13 WO PCT/US2022/072302 patent/WO2022241465A1/en not_active Ceased
- 2022-05-13 AU AU2022272740A patent/AU2022272740A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4574211A2 (en) | 2025-06-25 |
| JP2024518178A (ja) | 2024-04-25 |
| US20230022990A1 (en) | 2023-01-26 |
| WO2022241465A1 (en) | 2022-11-17 |
| AU2022272740A9 (en) | 2023-11-09 |
| CN117677394A (zh) | 2024-03-08 |
| EP4337243A1 (en) | 2024-03-20 |
| AU2022272740A1 (en) | 2023-11-02 |
| EP4574211A3 (en) | 2025-09-10 |
| TW202310868A (zh) | 2023-03-16 |
| KR20240035394A (ko) | 2024-03-15 |
| CA3218000A1 (en) | 2022-11-17 |
| IL308496A (en) | 2024-01-01 |
| MX2023012782A (es) | 2024-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022000019A2 (pt) | Composto da fórmula, composição farmacêutica e método de tratamento de câncer | |
| BR112014008789A2 (pt) | prevenção e tratamento de condições oculares | |
| BRPI0713755A8 (pt) | composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo | |
| EP3902525A4 (en) | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease | |
| BRPI0606172A2 (pt) | métodos e composições para o tratamento de distúrbios oculares | |
| BR112022015533A2 (pt) | Composições e métodos para tratar doenças oculares | |
| BR112022020147A2 (pt) | Compostos para tratar a doença de huntington | |
| MX2018001918A (es) | Aplicación cuantitativa periorbital de farmacos oftalmologicos. | |
| MX2024014117A (es) | Sales de ácido piperidinil-metil-purina-amina-d-tartárico, formas cristalinas y su uso en el tratamiento de enfermedades y condiciones médicas | |
| WO2020219486A9 (en) | Collagen peptide-based medicament compositions and devices and methods of production and use thereof | |
| MX2021015338A (es) | Composicion que comprende pridopidina y un analogo de la misma para el tratamiento de la enfermedad de huntington y sintomas de la misma. | |
| CL2023001596A1 (es) | Composiciones y métodos para el tratamiento de enfermedades oculares | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| EP4331614A4 (en) | USE OF A MEDICINE IN THE TREATMENT OF A TUMOR DISEASE | |
| MY208454A (en) | Anti-connective tissue growth factor antibody and application thereof | |
| CO2024007361A2 (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| EP4489746A4 (en) | Extended-release pharmaceutical compositions for the treatment of eye conditions | |
| BR112022003759A2 (pt) | Método e uso de pnpp-19 para prevenção e tratamento de doenças oculares | |
| EP4138841C0 (en) | FORMULATION FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | |
| BR112023018802A2 (pt) | Uso de hormônio de crescimento de ação prolongada para o tratamento de doenças induzidas por inflamação | |
| BR112022025128A2 (pt) | Composições e métodos para tratar doenças e distúrbios usando vesículas extracelulares microbianas de oscillospiraceae | |
| JOP20250015A1 (ar) | تركيبة صيدلانية للأجسام المضادة ضد cd20 واستخداماتها | |
| EP4419671A4 (en) | GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE | |
| EP4267163A4 (en) | COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONS | |
| EP4201406A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DEGENERATIVE BRAIN DISEASES COMPRISING ABEMACICLIB AS ACTIVE INGREDIENT |